

1 **Title:** Evidence that extracellular HSPB1 contributes to inflammation in alcohol-  
2 associated hepatitis

3 **Authors:** Anne-Marie C Overstreet<sup>1</sup>, McKenzie Burge<sup>1</sup>, Annette Bellar<sup>1</sup>, Megan McMullen<sup>1</sup>,  
4 Douglas Czarnecki<sup>1</sup>, Emily Huang<sup>1</sup>, Vai Pathak<sup>2</sup>, Chelsea Finney<sup>1</sup>, Raveena Vij<sup>3</sup>, Srinivasan  
5 Dasarathy<sup>1, 4, 5, 7</sup>, Jaividhya Dasarathy<sup>6, 7</sup>, David Stroom<sup>8</sup>, Nicole Welch<sup>1, 5</sup>, Daniel Rotroff<sup>2, 7</sup>,  
6 Adam M Schmitt<sup>3</sup>, Laura E Nagy<sup>1, 4, 5, 7, 9</sup>, Jeannette S Messer<sup>1, 7, 9</sup>

7 **Affiliations:**

8 <sup>1</sup>Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic,  
9 Cleveland, OH, USA

10 <sup>2</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA

11 <sup>3</sup>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New  
12 York.

13 <sup>4</sup>Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case  
14 Western Reserve University, Cleveland, OH, USA

15 <sup>5</sup>Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA

16 <sup>6</sup>Department of Family Medicine, MetroHealth Medical Center, Case Western Reserve  
17 University, Cleveland, OH, USA

18 <sup>7</sup>Northern Ohio Alcohol Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio,  
19 USA.

20 <sup>8</sup>Department of Psychiatry and Psychology, Cleveland Clinic Lutheran Hospital, Cleveland,  
21 Ohio, USA

22 <sup>9</sup>Center for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic,  
23 Cleveland, Ohio, USA.

24

25 **Corresponding author:**

26 Jeannette S Messer

27 E-mail: [messerj3@ccf.org](mailto:messerj3@ccf.org)

28 **Conflict of Interest:** The authors declare no conflicts of interest.

29 **Financial Support:** NIDDK 1K08DK114713 (JSM), NIAAA Northeast Ohio Alcohol Research  
30 Center Pilot and Feasibility Award (JSM), NIAAA Northeast Ohio Alcohol Research Center  
31 5P50AA024333 (LEN), NIAAA Johns Hopkins Clinical Resource for Alcoholic Hepatitis  
32 Investigation 5R24AA025017.

33 **Author Contributions:**

34 Conceptualization: JSM

35 Methodology: JSM, AMCO, MB, DR, AMS, LEN

36 Investigation: AMCO, MB, AB, MM, DC, EH, VP, CF, RV, SD, JD, DS, NW

37 Funding acquisition: JSM

38 Project administration: JSM

39 Supervision: JSM, AMCO, DR, AMS, LEN

40 Writing – original draft: JSM

41 Writing – review & editing: JSM, AMCO, MB, AMS, LEN

42 **Acknowledgements:** We thank Connor Hansen for assistance with manuscript preparation. The  
43 NIAAA funded Northeast Ohio Alcohol Research Center Clinical and Pre-clinical Cores were  
44 instrumental to this work. We also acknowledge the assistance of the Cleveland Clinic Light  
45 Microscopy Core in this study.

46 **Data and materials availability:** All data and code used in the analysis are available upon  
47 request. Materials used in this study are available upon request and with completion of the  
48 appropriate material transfer agreements.

49

---

50

51

---

52 **ABSTRACT**

53 **Background and aims:** Alcohol-associated hepatitis (AH) is the most life-threatening form of  
54 alcohol-associated liver disease (ALD). AH is characterized by severe inflammation attributed to  
55 increased levels of ethanol, microbes or microbial components, and damage-associated  
56 molecular pattern (DAMP) molecules in the liver. HSPB1 (Heat Shock Protein Family B (Small)  
57 Member 1; also known as Hsp25/27) is a DAMP that is rapidly increased in and released from  
58 cells experiencing stress, including hepatocytes. The goal of this study was to define the role of  
59 HSPB1 in AH pathophysiology.

60

61 **Methods:** Serum HSPB1 was measured in a retrospective study of 184 healthy controls (HC),  
62 heavy alcohol consumers (HA), patients with alcohol-associated cirrhosis (AC), and patients  
63 with AH recruited from major hospital centers. HSPB1 was also retrospectively evaluated in  
64 liver tissue from 10 HC and AH patients and an existing liver RNA-seq dataset. Finally, HSPB1  
65 was investigated in a murine Lieber-DeCarli diet model of early ALD as well as cellular models  
66 of ethanol stress in hepatocytes and hepatocyte-macrophage communication during ethanol  
67 stress.

68

69 **Results:** Circulating HSPB1 was significantly increased in AH patients and levels positively  
70 correlated with disease-severity scores. Likewise, HSPB1 was increased in the liver of patients  
71 with severe AH and in the liver of ethanol-fed mice. *In vitro*, ethanol-stressed hepatocytes  
72 released HSPB1, which then triggered TNF $\alpha$ -mediated inflammation in macrophages. Anti-  
73 HSPB1 antibody prevented TNF $\alpha$  release from macrophages exposed to media conditioned by  
74 ethanol-stressed hepatocytes.


75

76 **Conclusions:** Our findings support investigation of HSPB1 as both a biomarker and therapeutic  
77 target in ALD. Furthermore, this work demonstrates that anti-HSPB1 antibody is a rational  
78 approach to targeting HSPB1 with the potential to block inflammation and protect hepatocytes,  
79 without inactivating host defense.

80

81

## 82 GRAPHICAL ABSTRACT



83

84 **KEY WORDS:** alcohol-associated liver disease, Lieber-DeCarli, hepatocyte, macrophage,  
85 TNF $\alpha$ , heat shock protein 25, heat shock protein 27, damage-associated molecular pattern  
86 molecule

## 87 HIGHLIGHTS

- 88 • HSPB1 is significantly increased in serum and liver of patients with alcohol-associated  
89 hepatitis.
- 90 • Ethanol consumption leads to early increases in HSPB1 in the mouse liver.
- 91 • Hepatocytes subjected to ethanol stress release HSPB1 into the extracellular environment  
92 where it activates TNF $\alpha$ -mediated inflammation in macrophages.
- 93 • Anti-HSPB1 antibody blocks hepatocyte-triggered TNF $\alpha$  in a model of hepatocyte-  
94 macrophage communication during ethanol stress.

95

## 96 INTRODUCTION

97 Alcohol-associated liver disease (ALD) has reached a global prevalence of 4.8% and is now  
98 the most common cause of death due to excessive alcohol consumption in the United States  
99 (US).<sup>1,2</sup> In the US, ALD mortality increased 23% between 2019 and 2020, and claimed an  
100 estimated 45,290 American lives in 2022.<sup>1,3</sup> ALD has also become the leading indication for  
101 liver transplantation in the US, with a 63% increase in the number of patients listed for transplant  
102 between 2007 and 2017.<sup>4,5</sup> The term ALD broadly refers to any type of alcohol-induced liver  
103 damage and encompasses steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma.<sup>6</sup> In  
104 general, higher levels of alcohol consumption lead to more severe disease, but transitions  
105 between types of disease are unpredictable and ALD may go unrecognized until it becomes  
106 severe. These factors make it imperative to understand the pathophysiology of ALD in order to  
107 develop reliable diagnostics that predict risk of progression and therapies able to prevent severe  
108 forms of disease.

109 Alcohol-associated hepatitis (AH) is the most severe and life-threatening manifestation of  
110 ALD.<sup>7</sup> Mortality in severe AH approaches 50% within three months of diagnosis and rises to  
111 70% in patients that do not respond to corticosteroids.<sup>8</sup> Patients with AH present with rapid onset  
112 signs of liver failure and systemic inflammation.<sup>9</sup> Liver biopsy in these patients typically reveals  
113 steatosis, hepatocyte ballooning, Mallory-Denk hyaline inclusions, fibrosis, and infiltration by  
114 innate and adaptive immune cells.<sup>9</sup> The inflammatory cell infiltrate is accompanied by high  
115 levels of pro-inflammatory cytokines such as TNF $\alpha$  (tumor necrosis factor alpha), IL-1 $\beta$   
116 (interleukin-1 beta), and IL-6 (interleukin-6).<sup>9</sup> These factors suggest that AH is an acute  
117 inflammatory disease superimposed on chronic ALD.<sup>6</sup> They also argue that targeting  
118 inflammation could slow or reverse liver damage and decrease AH-associated mortality.

119 Inflammation results from both direct and indirect effects of alcohol on the liver. In the  
120 normal liver, tissue resident macrophages, called Kupffer cells, line the sinusoids and react to  
121 microbes, microbial components, and microbial products transmitted to the liver from the  
122 gastrointestinal (GI) tract.<sup>10</sup> These microbe-associated molecular pattern molecules (MAMPs)  
123 are detected by innate immune receptors on the surface or in the cytosol of macrophages and  
124 activate signaling cascades that lead to production and release of cytokines and chemokines. In  
125 the absence of alcohol, Kupffer cells are exposed to low levels of MAMPs, and inflammation is

126 limited in both extent and duration.<sup>11</sup> In contrast, alcohol can directly activate production and  
127 release of AH-associated cytokines, such as TNF $\alpha$ , from Kupffer cells or macrophages recruited  
128 into the liver.<sup>12</sup> Alcohol also damages the gut mucosal barrier, allowing increased translocation  
129 of MAMPs to the liver where they activate production of the same suite of pro-inflammatory  
130 cytokines and chemokines in Kupffer cells or recruited macrophages.<sup>13</sup> Finally, ethanol stressed  
131 hepatocytes can contribute to macrophage activation through release of damage-associated  
132 molecular pattern molecules (DAMPs). DAMPs are intracellular proteins that are naturally found  
133 at high levels inside cells or that are rapidly upregulated in response to stress. These danger  
134 signals are actively secreted from ethanol stressed cells or released into the extracellular  
135 environment secondary to cell death.<sup>14</sup> In the extracellular environment, DAMPs activate pattern  
136 recognition receptors (PRR) on macrophages, which leads to production of the same cytokines  
137 and chemokines that macrophages produce in response to MAMPs.<sup>15</sup>

138 One DAMP of particular interest in AH inflammation is HSPB1 (Heat Shock Protein Family  
139 B (Small) Member 1; also known as Hsp25/27). HSPB1 protein levels are rapidly increased in a  
140 wide range of cells subjected to MAMPs or oxidative stress.<sup>16-18</sup> In these cells, HSPB1 directly  
141 and indirectly counteracts cell damage and programmed cell death mechanisms, allowing them  
142 to survive in otherwise deadly conditions.<sup>19, 20</sup> Although HSPB1 has not been systematically  
143 evaluated in ALD, it has been implicated in alcohol-associated disease in other ways.  
144 Hepatocytes are primarily responsible for ethanol metabolism in the liver and this metabolism  
145 generates reactive oxygen species that accumulate and cause oxidative stress and cell damage  
146 with high or prolonged alcohol use.<sup>21</sup> There is a large body of literature demonstrating that  
147 HSPB1 acts to prevent programmed cell death in cells experiencing oxidative stress.<sup>22</sup> A role for  
148 HSPB1 in cellular responses to ethanol is further supported by studies in astrocytes, which  
149 showed that ethanol challenge leads to increased HSPB1 gene expression in in these cells.<sup>23</sup>  
150 Extracellular HSPB1 is of particular interest in ALD since patients with hepatocellular  
151 carcinoma have increased levels of HSPB1 and anti-HSPB1 antibodies in their blood; increases  
152 that were linked to a history of alcohol use in some studies.<sup>24-28</sup> HSPB1 is reportedly released  
153 from stressed cells, including hepatocytes to activate PRR on adjacent cells.<sup>29-32</sup> HSPB1-  
154 mediated PRR activation then leads to production and release of the AH-associated cytokines  
155 TNF $\alpha$  and IL-1 $\beta$  from macrophages.<sup>32, 33</sup>

156 These factors led us to examine HSPB1 in AH, with the goal of understanding the role that  
157 this protein plays in inflammation and liver damage caused by alcohol consumption. We found  
158 that patients with AH have significantly higher levels of HSPB1 in both their blood and liver  
159 than liver disease free controls or patients with alcohol-associated cirrhosis (AC). This suggested  
160 that increases in HSPB1 were related to the higher level of inflammation in AH. In a murine  
161 model of chronic alcohol consumption (CAC), HSPB1 was increased in the liver prior to  
162 significant liver damage, meaning that it does not result from inflammation. Similar to our  
163 human and animal studies, HSPB1 protein was rapidly increased in and released from  
164 hepatocytes stressed with ethanol *in vitro*. In the extracellular environment, HSPB1 promoted  
165 inflammation by triggering TNF $\alpha$  release from macrophages. The importance of HSPB1 in  
166 ethanol-activated inflammation was reinforced by the fact that anti-HSPB1 antibody almost  
167 completely mitigated TNF $\alpha$  release from macrophages treated with media conditioned by  
168 ethanol stressed hepatocytes. Together, these findings establish a key role for HSPB1 in the  
169 inflammation of AH and identify it as a potential biomarker and therapeutic target for this  
170 intractable disease.

171

## 172 RESULTS

### 173 **Circulating HSPB1 is increased in ALD patients with the highest levels in severe AH.**

174 Predicting the course of ALD in a given patient is extremely challenging. Nearly all patients  
175 consuming high levels of alcohol develop steatosis and many never progress to more severe  
176 disease.<sup>9</sup> However, patients can progress to life-threatening disease quickly and without any prior  
177 indication. This makes development of biomarkers that can identify patients at risk of  
178 progression vital in ALD. The ideal biomarker would be amenable to non-invasive monitoring,  
179 differentiate liver disease caused by alcohol use from other causes, predict risk of acute  
180 destabilization, and be targetable to prevent severe disease.

181 Identification of HSPB1 as a potential DAMP and biomarker of inflammation in AH led us  
182 to retrospectively measure HSPB1 in serum from healthy controls (HC), heavy alcohol  
183 consumers (HA), patients with AC, and patients with AH (**Table 1**). Levels of HSPB1 were  
184 similar in the groups without liver disease (HC and HA). However, HSPB1 was significantly

185 higher in patients with ALD (AC and AH) versus those without liver disease (**Fig. 1A**).  
186 Comparison of serum HSPB1 concentrations between AC and AH further revealed that HSPB1  
187 was significantly higher in AH than AC. We next investigated relationships between disease  
188 severity and HSPB1 in the ALD groups (**Table 2**). There was no correlation between HSPB1 and  
189 disease severity in AC and no difference between HSPB1 in patients with severe versus mild-  
190 moderate AC (**Fig. 1B, C**). However, within the AH group, HSPB1 increased as disease severity  
191 increased and levels of HSPB1 were significantly higher in severe versus mild-moderate disease  
192 (**Fig. 1D, E**). HSPB1 levels were not related to age or sex, despite literature describing HSPB1 as  
193 an estrogen responsive gene (**Fig. 1F, G**).<sup>31</sup> Thus, high circulating HSPB1 is a feature of severe  
194 AH.

195 Several post-translational modifications have been described for intracellular HSPB1,  
196 including phosphorylation. Human HSPB1 contains three serines capable of accepting a  
197 phospho-group, serine 15, serine 78, and serine 82.<sup>34</sup> Phosphorylation of these serines determines  
198 oligomerization and distribution of HSPB1 inside cells, but the role of phosphorylation in  
199 extracellular functions is far less clear. Serine 15 phosphorylation is associated with HSPB1  
200 distribution to insoluble cell components during hydrogen peroxide induced oxidative stress,  
201 making it unlikely to be found in extracellular HSPB1 during ethanol stress.<sup>18</sup> This made us  
202 focus on HSPB1 phosphorylation at serines 78 and 82 in the patient blood (**Table 3**). Of the  
203 tested samples, only 3 of 57 were positive for phosphorylated-HSPB1, two of the positive  
204 samples were in the AC group and one was in the AH group (**Fig. 1H**). All of the samples  
205 positive for phosphorylated HSPB1 were also positive for total HSPB1. This suggests that  
206 extracellular HSPB1 is only rarely phosphorylated in ALD patients and so, phosphorylation is  
207 not likely to be involved in its extracellular functions in AH.




208

Demographics	Healthy Control	High Alcohol	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis
Total	51	41	49	43
Age, mean, (SD), [range]	42.8, ( $\pm$ 14.0), [21-66]	46.4, ( $\pm$ 13.8), [21-65]	50.7, ( $\pm$ 9.7), [31-69]	46.7, ( $\pm$ 9.1), [29-62]
Age in males	44.6, ( $\pm$ 12.9), [24-63]	49.4, ( $\pm$ 12.3), [27-65]	52.3, ( $\pm$ 8.9), [35-69]	48.8, ( $\pm$ 9.0), [33-62]
Age in females	42.8, ( $\pm$ 14.0), [21-66]	43.3, ( $\pm$ 14.8), [21-63]	46.5, ( $\pm$ 10.8), [31-66]	44.8, ( $\pm$ 9.0), [29-57]
<b>Sex, n (%)</b>				
Male	19 (37.3%)	21 (51.2%)	35 (71.4%)	21 (48.8%)
Female	32 (62.7%)	20 (48.8%)	14 (28.6%)	22 (51.2%)
<b>Ethnicity, n (%)</b>				
Asian	1 (2.0%)	0	1 (2.0%)	0
Black	5 (9.8%)	18 (43.9%)	7 (14.3%)	2 (4.7%)
Hispanic	1 (2.0%)	1 (2.4%)	0	0
White	44 (86.7%)	21 (51.2%)	39 (79.6%)	41 (95.3%)
Unknown	0	1 (2.4%)	2 (4.1%)	0

209

210 **Table 1. Patient demographics in studies of circulating HSPB1.**

211



212

213 **Figure 1. Circulating HSPB1 is increased in ALD patients.**

214 **A**, Violin plot of HSPB1 concentration in patient sera measured by ELISA. **B**, Linear regression of HSPB1  
 215 concentration and Child-Pugh score of AC patients. **C**, HSPB1 concentration in AC patients with mild-moderate  
 216 ( $\leq 8$ ) vs. severe ( $> 8$ ) disease scores (Child-Pugh). **D**, Linear regression of HSPB1 concentration vs. MELD score of  
 217 AH patients. **E**, HSPB1 concentration in AH patients with mild-moderate ( $\leq 22$ ) vs. severe ( $> 22$ ) disease scores  
 218 (MELD). **F**, Linear regression of HSPB1 concentration vs. age in all patients. **G**, HSPB1 concentration in male vs.  
 219 female patients. **H**, Phosphorylated HSPB1 concentration in patient sera measured by ELISA. All data plotted as  
 220 mean  $\pm$  SEM. A,H. Kruskal-Wallis test with a Dunn's multiple comparisons post-hoc test. B, D, F. Simple Linear  
 221 Regression. C, E, G. Mann-Whitney test. HC, healthy control; HA, high alcohol consumer; AC, alcohol-associated  
 222 cirrhosis; AH, alcohol-associated hepatitis. n.s.  $P > 0.05$ , \*  $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ .  
 223

224

Demographics	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis
Total	31	43
Age, mean, (SD), [range]	50.6, ( $\pm 9.9$ ), [31-68]	46.7, ( $\pm 9.1$ ), [29-62]
Age in males	52.2, ( $\pm 9.0$ ), [38-68]	48.8, ( $\pm 9.0$ ), [33-62]
Age in females	47.8, ( $\pm 11.1$ ), [31-66]	44.8, ( $\pm 9.0$ ), [29-57]
Score	Child-Pugh	MELD
Score, mean, (SD), [range]	8.4, ( $\pm 2.2$ ), [5-13]	25.8, ( $\pm 6.5$ ), [16-43]
Score in males	8.5, ( $\pm 2.3$ ), [5-13]	27.5, ( $\pm 7.3$ ), [18-43]
Score in females	8.4, ( $\pm 2.2$ ), [5-12]	24.1, ( $\pm 5.2$ ), [16-36]
Sex, n (%)		
Male	20 (64.5%)	21 (48.8%)
Female	11 (35.5%)	22 (51.2%)
Ethnicity, n (%)		
Asian	0	0
Black	1 (3.2%)	2 (4.7%)
Hispanic	0	0
White	30 (96.8%)	41 (95.3%)
Unknown	0	0

225

226 **Table 2. Patient demographics and clinical data in studies of circulating HSPB1 and**  
 227 **disease severity.**

228

Demographics	Healthy Control	High Alcohol	Alcohol-associated Cirrhosis	Alcohol-associated Hepatitis
Total	15	12	13	17
Age, mean, (SD), [range]	40.4, ( $\pm 12.7$ ), [23-62]	42.3, ( $\pm 12.8$ ), [24-63]	47.9, ( $\pm 8.0$ ), [35-60]	45.6, ( $\pm 9.4$ ), [30-60]
Age in males	43.0, ( $\pm 12.4$ ), [25-62]	47.0, ( $\pm 12.8$ ), [30-63]	49.3, ( $\pm 5.4$ ), [41-56]	45.9, ( $\pm 9.6$ ), [33-60]
Age in females	37.4, ( $\pm 13.2$ ), [23-62]	32.8, ( $\pm 6.0$ ), [24-37]	46.6, ( $\pm 10.0$ ), [35-60]	44.6, ( $\pm 9.6$ ), [30-55]
Score			Child-Pugh	MELD
Score, mean, (SD), [range]			8.4, ( $\pm 3.4$ ), [5-13]	22.3, ( $\pm 3.9$ ), [16-30]
Score in males			8.7, ( $\pm 2.4$ ), [7-13]	23.4, ( $\pm 4.2$ ), [18-30]
Score in females			8.1, ( $\pm 2.5$ ), [5-12]	21.1, ( $\pm 3.2$ ), [16-27]
Sex, n (%)				
Male	8 (53.3%)	8 (66.7%)	6 (46.2%)	8 (47.1%)
Female	7 (46.7%)	4 (33.3%)	7 (53.8%)	9 (52.9%)
Ethnicity, n (%)				
Asian	0	0	0	0
Black	2 (13.3%)	2 (16.7%)	0	0
Hispanic	1 (6.7%)	0	0	0
White	12 (80.0%)	9 (75.0%)	13 (100%)	17 (100%)
Unknown	0	1 (8.3%)	0	0

229

230 **Table 3. Patient demographics and clinical data in studies of phosphorylated HSPB1 in**  
 231 **serum.**


232

233 **HSPB1 is increased in the liver of patients with AH.** We next considered the source of  
 234 circulating HSPB1 in patients with severe AH. The liver is responsible for the majority of

235 ethanol metabolism and is subject to high levels of oxidative stress generated by the highly  
236 reactive byproducts of this metabolism.<sup>35</sup> A large body of literature has demonstrated that  
237 HSPB1 is cytoprotective in cells experiencing oxidative stress.<sup>36</sup> HSPB1 release from stressed  
238 hepatocytes has also been reported.<sup>29</sup> This suggested that the liver was the most likely source of  
239 circulating HSPB1 in the AH patients.

240 In the United States, very few ALD patients undergo diagnostic liver biopsy, so large  
241 numbers of liver samples from these patients are difficult to obtain. We were fortunate to acquire  
242 banked liver lysates from five patients with severe AH and five healthy controls (**Table 4**). These  
243 samples were obtained during liver transplantation from patients with severe AH and healthy  
244 donor livers. There was a clear difference in HSPB1 between HC and AH, with HSPB1  
245 significantly higher in AH than HC (**Fig. 2A, B**). We also utilized existing RNA-seq datasets to  
246 evaluate HSPB1 gene expression in the livers of patients with AH of varying severity or other  
247 types of liver disease. In non-severe and severe AH (liver biopsies or explanted liver), HSPB1  
248 gene expression was significantly higher than both HC and any other type of liver disease (**Fig.**  
249 **2C, D, E**). Interestingly, metabolic dysfunction-associated steatotic liver disease (MASLD) was  
250 not associated with increased HSPB1 gene expression. This is similar to reports in the literature  
251 that HSPB1 in circulation does not differ between pediatric healthy controls and patients with  
252 MASLD and that ballooning degeneration is associated with decreased HSPB1 gene expression  
253 and protein in livers from adult MASLD patients.<sup>37, 38</sup> Taken together, these data identify the  
254 liver as an important source of circulating HSPB1 in AH and suggest that high levels of HSPB1  
255 in the liver are linked to ALD, but not MASLD.

256



257

258 **Figure 2. HSPB1 is increased in the liver of patients with AH**

259 **A**, Representative immunoblot for HSPB1 and GAPDH in HC and AH liver samples. **B**, HSPB1 protein  
 260 concentration relative to GAPDH as measured by densitometry in immunoblots represented in (**A**). **C**, HSPB1 gene  
 261 expression in RNA-seq analysis of liver from HC, AH, AC, MASLD, and HCV. **D**, Forrest plot depicting Log2 fold  
 262 changes in HSPB1 expression in samples described in (**C**). Patients with various types of liver disease were  
 263 compared to healthy controls. **E**, Forrest plot depicting Log2 fold changes in HSPB1 expression in samples  
 264 described in (**C**). Patients with various types of liver disease were compared to patients with severe AH. Data plotted  
 265 as mean  $\pm$  SD, except C,D,E which is mean  $\pm$  SEM. B. Mann-Whitney test. C, D. DeSeq2. HC, healthy control; AH  
 266 alcohol-associated hepatitis, MASLD, metabolic dysfunction associated with steatotic liver disease; HCV, hepatitis  
 267 C virus; TPM, transcripts per million. n.s.  $P > 0.05$ , \*  $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ .

268

269

Demographics	Healthy Control	Alcohol-associated Hepatitis
Total	5	5
Age, mean, (SD)	45.6, ( $\pm$ 6.7)	40.8, ( $\pm$ 3.5)
<b>Sex, n (%)</b>		
Male	3 (60%)	3 (60%)
Female	2 (40%)	2 (40%)
<b>Clinical Data</b>		
Decompensation (n, (%))	N/A	5 (100%)
Sepsis (n, (%))	N/A	0 (0%)
Maddrey's discriminant function	N/A	102.5 ( $\pm$ 27.7)
Total bilirubin (mg/dL)	N/A	25.2 ( $\pm$ 5.1)
Prothrombin time (sec)	N/A	32.4 ( $\pm$ 5.7)

270

271 **Table 4. Patient demographics and clinical data for samples used for HSPB1 liver lysate**  
272 **immunoblot.**


273

274 **Chronic ethanol consumption increases HSPB1 in murine liver.** HSPB1 could be increased  
275 in the liver secondary to damage, or it could be contributing to damage. To distinguish between  
276 these possibilities, we examined livers using a murine model of CAC. Mice were fed the Lieber-  
277 DeCarli liquid diet with increasing amounts of ethanol over 25 days or a calorie-matched diet  
278 supplemented with maltodextrin (**Fig. 3A**).<sup>39</sup> The final concentration of ethanol in this model is  
279 6% and that concentration is maintained for one week. Controls were pair-fed, meaning that their  
280 calorie intake was adjusted daily to match that of a paired ethanol-consuming mouse. This model  
281 replicates early or mild ALD. We chose this model because our goal was to determine whether  
282 increased liver HSPB1 results from liver damage or precedes and therefore potentially causes  
283 liver pathology seen in AH.

284 Ethanol-fed (EtOH) mice had significantly higher levels of both HSPB1 mRNA and protein  
285 in their livers than pair-fed (Pair) controls (**Fig. 3B, C**). Immunofluorescence staining of liver  
286 sections from these mice identified weak HSPB1 staining in periportal regions and high HSPB1  
287 staining around central veins in EtOH mice (**Fig. 3D, E**). Periportal hepatocytes are exposed to  
288 high levels of gut-derived components, including MAMPs.<sup>40</sup> Ethanol consumption, especially at  
289 high levels, damages the gut epithelium, allowing increased translocation of microbes, microbial  
290 components, or microbial products across the barrier and into the liver through portal

291 circulation.<sup>41</sup> HSPB1 production in response to MAMPs such as lipopolysaccharide and flagellin  
292 is well-documented and is likely responsible for the weak periportal HSPB1 staining in the EtOH  
293 mice.<sup>16, 17</sup> In contrast, HSPB1 staining was pronounced in pericentral hepatocytes, which are  
294 primarily responsible for ethanol metabolism in the liver.<sup>42</sup> Of note, hepatocytes positive for  
295 HSPB1 were also filled with lipid droplets and HSPB1 levels in the liver were positively  
296 correlated with triglyceride levels in the blood of these mice (**Fig. 3F, G**). This is in keeping with  
297 a report that HSPB1 knockout mice have lower levels of triglycerides in their blood.<sup>43</sup> The  
298 presence of HSPB1 in the ethanol-stressed liver prior to damage was reinforced by the fact that  
299 circulating aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were similar in  
300 EtOH and Pair mice (**Fig. 3H, I**). Since HSPB1 is increased in the ethanol-stressed liver prior to  
301 the onset of significant damage, the increased HSPB1 is more likely to be a cause of damage  
302 than the result of damage.

303



304

305 **Figure 3. Chronic ethanol consumption increases HSPB1 in murine liver.**

306 **A**, Illustration of murine model of CAC. **B**, Relative gene expression of HSPB1 in the liver of Pair and EtOH mice  
 307 measured by qRT-PCR. **C**, HSPB1 concentration in the liver of Pair and EtOH mice measured by ELISA. **D&E**,  
 308 Immunostaining for HSPB1 (yellow) and DNA (Hoechst, blue) in pair- and EtOH-fed mice. Scale bar = 100  $\mu$ m.  
 309 Images in **(D)** are focused on periportal hepatocytes and images in **(E)** are focused on pericentral hepatocytes.  
 310 Images are representative of 12 Pair and 11 EtOH mice. **F**, High-magnification image of HSPB1 (yellow) and DNA  
 311 (Hoechst, blue) immunofluorescence in the liver of EtOH mice. Scale bar = 50  $\mu$ m. **G**, Linear regression analysis of  
 312 liver HSPB1 and triglyceride levels in Pair and EtOH mice. **H**, AST levels in serum from Pair and EtOH mice. **I**,  
 313 ALT levels in serum from Pair and EtOH mice. Data are plotted as mean  $\pm$  SD. B, C, H, I. Unpaired T-test. G.  
 314 Simple Linear Regression. CAC, chronic alcohol consumption; Pair, pair-fed mice; EtOH, ethanol-fed mice; TG,  
 315 triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase. n.s.  $P > 0.05$ , \*  $P \leq 0.05$ , \*\*  $P \leq$   
 316 0.01, \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ .

317




318

319 **Ethanol stressed hepatocytes release HSPB1 into the extracellular environment.** Findings  
320 from patients and mice chronically consuming alcohol identified the liver, and specifically  
321 hepatocytes, as the likely source of circulating HSPB1 in AH. To verify ethanol activated  
322 HSPB1 release from hepatocytes, we performed *in vitro* studies of ethanol challenge using  
323 hepatocyte cell lines.

324 Ethanol exposure rapidly and robustly increased HSPB1 protein in HepG2 cells, even before  
325 HSPB1 mRNA levels increased (**Fig. 4A, B, C**). This type of rapid upregulation without the  
326 need for increased transcription has been reported for heat shock proteins, including HSPB1 with  
327 other types of cell stress.<sup>44, 45</sup> It also fits with the extensively documented roles that HSPB1 plays  
328 in cellular survival during many different types of stress, including oxidative stress. Since our  
329 primary interest in hepatocyte produced HSPB1 was in HSPB1 release from hepatocytes, we  
330 investigated whether ethanol challenge led to increased amounts of HSPB1 in the hepatocyte  
331 media. Exposure to ethanol led to an approximately 3-fold increase in extracellular HSPB1  
332 within 1 hr. (**Fig. 4D**). This increase was triggered in response to ethanol metabolism, not cell  
333 membrane damage, since inhibiting ethanol metabolism with 4-methylpyrazole (4-MP)  
334 completely eliminated HSPB1 release in response to ethanol challenge (**Fig. 4E, F**). We  
335 performed these experiments in two hepatocyte cell lines, HepG2 (human) and AML12 (murine),  
336 to account for any cell-line related effects on ethanol metabolism or HSPB1 production and  
337 release. Thus, ethanol metabolism leads to rapid increases in both intracellular HSPB1 and  
338 HSPB1 released from hepatocytes.

339



340

341 **Figure 4. HSPB1 is increased in EtOH-stressed hepatocytes and released into the**  
 342 **extracellular environment.**

343 **A**, Immunoblotting for HSBP1 and GAPDH in HepG2 cells exposed to vehicle control or 2.5 mM (1.5%) EtOH for  
 344 1 hr. **B**, Intracellular HSPB1 concentration measured in cell lysates of HepG2 cells exposed to vehicle control or 2.5  
 345 mM EtOH for 1 hr. by ELISA. **C**, HSPB1 gene expression relative to GAPDH in HepG2 cells exposed to vehicle  
 346 control or 2.5 mM EtOH for 1 hr. by qRT-PCR. **D**, Extracellular HSPB1 concentration measured in culture media  
 347 from HepG2 cells exposed to vehicle control or 2.5 mM EtOH for 1 hr. by ELISA. **E**, Extracellular HSPB1  
 348 concentration measured in cell media from HepG2 cells exposed to vehicle control, 5 mM 4MP, 2.5 mM EtOH, or  
 349 2.5 mM EtOH and 5 mM 4MP for 1 hr. by ELISA. **F**, Extracellular HSPB1 concentration measured in cell media  
 350 from AML12 cells exposed to vehicle control, 5 mM 4MP, 2.5 mM EtOH, or 2.5 mM EtOH and 5 mM 4MP for 1  
 351 hr. by ELISA. Data are plotted as mean  $\pm$  SD. B, C, D. Unpaired T-test. E, F. One-way ANOVA with a Tukey's  
 352 multiple comparisons post-hoc test. n.s.  $P > 0.05$ , \*  $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ .

353

354 **HSPB1 released from ethanol stressed hepatocytes promotes liver-damaging inflammation.**


355 In the extracellular environment, HSPB1 functions as a DAMP to amplify macrophage  
 356 inflammatory responses, including those involving  $\text{TNF}\alpha$ .<sup>32, 33</sup>  $\text{TNF}\alpha$  is of particular interest  
 357 since it has been implicated in liver damage and hepatocyte death in patients with AH.<sup>46</sup> This  
 358 cytokine is also reportedly increased in plasma from liver disease patients with elevated HSPB1  
 359 in circulating lymphomonocytes.<sup>47</sup> Despite minimal changes to the hepatic parenchyma in our

360 EtOH mice receiving the Lieber-DeCarli diet, there was a higher level of TNF $\alpha$  in the liver of  
361 these mice than Pair controls (**Fig. 5A**). Furthermore, the level of TNF $\alpha$  was related to the level  
362 of HSPB1 in the liver in these mice (**Fig. 5B**).

363 Macrophages are the primary producers of pro-inflammatory cytokines, including TNF $\alpha$  in  
364 the ethanol-stressed liver.<sup>12</sup> Our finding that ethanol stress triggers HSPB1 release from  
365 hepatocytes led us to consider that extracellular HSPB1 could act on nearby macrophages to  
366 amplify TNF $\alpha$  secretion during CAC. As previously reported, ethanol robustly increased TNF $\alpha$   
367 secretion by macrophages within one hour of exposure (**Fig. 5C**).<sup>48</sup> In contrast, TNF $\alpha$  secretion  
368 was unchanged in HSPB1 treated macrophages at 1 hour. However, at 24 hours, TNF $\alpha$  secretion  
369 was significantly increased in HSPB1 treated macrophages and levels were essentially identical  
370 to ethanol-exposed macrophages (**Fig. 5D**). The combination of HSPB1 and ethanol increased  
371 TNF $\alpha$  release slightly over each component alone. These data suggest that the mechanisms and  
372 kinetics of TNF $\alpha$  secretion elicited by HSPB1 and ethanol differ, but not the inflammatory  
373 outcome. They also demonstrate that macrophages need never encounter ethanol or MAMPs  
374 directly to activate inflammation during CAC. HSPB1 is sufficient to activate TNF $\alpha$  mediated  
375 inflammation and has the potential to amplify inflammation triggered by either ethanol or  
376 MAMPs.

377 We next investigated whether blocking extracellular HSPB1 is sufficient to inhibit TNF $\alpha$   
378 release from macrophages exposed to ethanol stressed hepatocytes. Media conditioned by  
379 ethanol stressed HepG2 cells was used to replicate the natural form and amount of HSPB1  
380 released from hepatocytes in these experiments. We added anti-HSPB1 antibody to the  
381 hepatocyte conditioned media, then added the treated media to macrophages, and measured  
382 TNF $\alpha$  release. The addition of anti-HSPB1 antibody reduced TNF $\alpha$  release from macrophages  
383 significantly (**Fig. 5E**). Overall, our data suggest that HSPB1 is an important initiator of TNF $\alpha$   
384 dependent inflammation and hepatocyte death in AH. They also show that anti-HSPB1 antibody  
385 is a rational therapeutic strategy to protect the ethanol stressed liver.

386



387

388 **Figure 5. Extracellular HSPB1 promotes liver-damaging inflammation.**

389 **A**, TNF $\alpha$  concentration in liver lysates from of Pair and EtOH mice measured by ELISA. **B**, Linear regression  
 390 analysis of liver HSPB1 and TNF $\alpha$  in Pair and EtOH mice. **C**, TNF $\alpha$  concentration measured in RAW264.7 cells  
 391 after 1 hr. of treatment with 3  $\mu$ M HSPB1, 2.5 mM (1.5%) EtOH, or both 2.5 mM EtOH and 3  $\mu$ M HSPB1 by  
 392 ELISA. **D**, TNF $\alpha$  concentration measured in RAW264.7 cells after 24 hr. of treatment with 3  $\mu$ M HSPB1, 2.5 mM  
 393 EtOH, or both 2.5 mM EtOH and 3  $\mu$ M HSPB1 by ELISA. **E**, TNF $\alpha$  concentration in RAW264.7 cells after  
 394 exposure to EtOH stressed HepG2 (2.5 mM EtOH for 24 hr.) conditioned media with or with or without 2.5 mg/ml  
 395 anti-HSPB1 antibody measured by ELISA. Data are plotted as mean  $\pm$  SD. A. Unpaired T-test. B. Simple Linear  
 396 Regression. C, D, E. One-ANOVA with a Tukey's multiple comparisons post-hoc test. n.s.  $P > 0.05$ , \*  $P \leq 0.05$ , \*\*  
 397  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$ .

398

399 **DISCUSSION**

400 Inflammation destabilizes ALD, leading to disease progression and AH. In this study, we  
 401 discovered that HSPB1 is increased in the liver and blood of patients with severe AH. We also

402 demonstrated that HSPB1 is released from ethanol stressed hepatocytes and triggers  
403 inflammation linked with progression to AH and increased mortality in ALD. Extracellular  
404 HSPB1 has been identified as a DAMP in published literature. For example, cardiomyocytes  
405 subjected to ischemia and reperfusion injury have been shown to release HSPB1 to activate toll  
406 like receptor 2/4 on endothelial cells.<sup>49</sup> Extracellular HSPB1 is also reported to trigger TNF $\alpha$   
407 inflammation in macrophages.<sup>32, 33</sup> Our work shows that HSPB1 fits the classical profile of a  
408 DAMP in ALD, in that it activates macrophages when released from ethanol stressed cells.  
409 However, it is unlike many other DAMPs, in that it normally present at low levels and is rapidly  
410 increased in response to ethanol. In CAC, this means that it is released from cells that have  
411 encountered ethanol or evidence of ethanol toxicity (i.e., MAMPs) and upregulated HSPB1.  
412 Release of DAMPs is generally considered to be a product of dead cells.<sup>15</sup> However, there is  
413 ample evidence that HSPB1 is secreted by live cells, including hepatocytes.<sup>29, 50</sup>

414 This work not only adds HSPB1 to the list of DAMPs identified in ALD, it also demonstrates  
415 that this protein is a cause of TNF $\alpha$  mediated inflammation associated with the progression to  
416 AH. Inflammation was established as a therapeutic target in AH decades ago.<sup>51</sup> Since that time,  
417 preclinical and clinical studies have identified inflammatory pathways and mediators that  
418 contribute to liver damage and hepatocyte death. The cytokine TNF $\alpha$  is among the inflammatory  
419 mediators most strongly linked to AH. Patients with AH have higher levels of TNF $\alpha$  in their  
420 blood than healthy controls and TNF $\alpha$  is increased in the liver of animals chronically consuming  
421 ethanol versus control animals.<sup>52-54</sup> At the cellular level, ethanol stabilizes TNF $\alpha$  mRNA in  
422 macrophages, leading to rapid increases in TNF $\alpha$  production and release from these cells.<sup>48, 55, 56</sup>  
423 Macrophages also produce TNF $\alpha$  in response to MAMPs and DAMPs that are increased in  
424 CAC.<sup>57</sup> Alcohol increases MAMP delivery to the liver by damaging the intestinal epithelium and  
425 allowing translocation across the gut mucosal barrier.<sup>58</sup> Alcohol also increases DAMPs in the  
426 liver due to secretion from stressed cells and release from dead or dying cells.<sup>15</sup> The high level of  
427 TNF $\alpha$  generated in these conditions activates programmed cell death in hepatocytes both *in vitro*  
428 and *in vivo*.<sup>46, 59</sup> In pre-clinical models, TNF receptor 1 knockout or anti-TNF $\alpha$  antibody protect  
429 animals from liver damage.<sup>54, 60</sup> However, clinical studies of anti-TNF $\alpha$  antibodies were halted  
430 early due to life-threatening infections in the AH patients.<sup>61, 62</sup> This highlights the importance of  
431 targeting liver damaging “sterile inflammation” while leaving host defense intact in AH.

432 The first step in targeting liver damaging sterile inflammation is identifying appropriate  
433 therapeutic targets and biomarkers for those targets. Our findings suggest that HSPB1 is a  
434 component of sterile inflammation in AH and therefore warrants further investigation as a  
435 biomarker and/or therapeutic target in this disease. HSPB1 fits several criteria for these  
436 applications: 1) Differences in HSPB1 can be measured in the blood. 2) HSPB1 is significantly  
437 higher in AH than other forms of liver disease and increases with increasing disease severity. 3)  
438 HSPB1 is upstream of liver-damaging inflammation and so potentially indicates risk for  
439 inflammation before it occurs. 4) Blocking HSPB1 action blocks TNF $\alpha$  mediated inflammation  
440 *in vitro*.

441 HSPB1 has already been proposed as a biomarker for disease severity in cancers, most  
442 notably hepatocellular carcinoma (HCC).<sup>27</sup> In HCC, HSPB1 is increased in lymphomonocytes  
443 and tumor tissue, especially in cases associated with a history of alcohol use.<sup>28, 47</sup> High levels of  
444 liver HSPB1 have also been associated with increased immune cell infiltration into tumor tissue  
445 and worse prognosis in HCC.<sup>27, 28</sup> Alcohol-associated liver diseases have also been linked to  
446 naturally occurring anti-HSPB1 antibodies.<sup>25</sup> These antibodies could be important both  
447 diagnostically and therapeutically. Concern has been raised that anti-HSPB1 antibodies could  
448 interfere with measurement of HSPB1 in standard, ELISA-based assays.<sup>31</sup> Additionally,  
449 naturally occurring anti-HSPB1 antibodies could influence HSPB1 functions and/or interfere  
450 with antibody-based therapeutics directed at HSPB1. Here, we utilized a commercially available  
451 ELISA, and results supported that this assay is able to measure the form and amount of HSPB1  
452 released from ethanol stressed cells. We did not measure anti-HSPB1 antibodies in our patient  
453 population due to limited sample volume and this limitation also precluded any investigation of  
454 effects of naturally occurring anti-HSPB1 antibody on extracellular HSPB1 functions. These  
455 types of studies will need to be performed in the future if HSPB1 is developed as a therapeutic  
456 target for AH.

457 Development of HSPB1 as a biomarker for AH will also require prospective studies that  
458 measure HSPB1 concentration throughout the course of disease. High levels of HSPB1 may  
459 predict which patients are at highest risk for disease exacerbation and most in need of intense  
460 monitoring or early liver transplantation. Conversely, low HSPB1 may be useful to stratify  
461 patients into a low-risk group, since HSPB1 was no different in our patients consuming large

462 amounts of alcohol without liver disease and healthy controls. Multiple timepoint sampling  
463 would reveal whether a single cut-off value of HSPB1 or changing levels of circulating HSPB1  
464 would be most useful clinically.

465       Aside from its potential to serve as a biomarker in ALD, HSPB1 also shows promise as a  
466 therapeutic target in the inflammation of AH. Our data show that HSPB1 is upstream of TNF $\alpha$   
467 mediated inflammation. Extracellular HSPB1 has also been reported to activate a second  
468 macrophage inflammatory mediator implicated in AH, IL-1 $\beta$ . Therefore, targeting HSPB1 has  
469 the potential to block activation of multiple inflammatory pathways and broadly protect  
470 hepatocytes from inflammation activated cell death programs. Our work specifically  
471 demonstrates the potential efficacy of an anti-HSPB1 antibody to interrupt inflammation in AH.  
472 We would expect this type of agent to be particularly effective at blocking the DAMP function of  
473 HSPB1, while leaving intracellular, cytoprotective functions of HSPB1 intact. It would also  
474 preserve TNF $\alpha$  activation by microbes and allow TNF $\alpha$  mediated inflammation in host defense  
475 mounted by macrophages.

476       Together, our findings directly link HSPB1 to inflammation in AH and provide a potential  
477 explanation for disease exacerbation. We propose that HSPB1 is highly upregulated in  
478 hepatocytes in response to ethanol metabolism and released into the extracellular environment  
479 where it activates TNF $\alpha$  in macrophages. When ethanol exposure is limited in amount or  
480 duration, we presume that HSPB1 is both cytoprotective in hepatocytes and promotes tissue  
481 repair through activation of low levels of TNF $\alpha$  at the site of damage. Conversely, when ethanol  
482 exposure occurs at high levels or is sustained for long periods of time, the high levels of TNF $\alpha$   
483 could overwhelm HSPB1 cryoprotection, leading to hepatocyte death. Additionally, the dying  
484 ethanol stressed hepatocytes would be expected to release high levels of HSPB1, which would  
485 amplify TNF $\alpha$  production and causes even more hepatocyte death leading to a feed-forward or  
486 vicious cycle. Our data support this model in a number of ways. However, several key questions  
487 do remain unanswered. First, does extracellular HSPB1 act on cells other than macrophages  
488 during CAC? Hepatic stellate cells and other infiltrating innate and adaptive immune cells could  
489 also be influenced by HSPB1 to contribute to disease. Second, does anti-HSPB1 antibody inhibit  
490 inflammation in the complex context of the intact liver during CAC? To answer this question, we  
491 need to test our anti-HSPB1 antibody in an animal model that mimics more severe, inflammatory

492 ALD. This experiment would also reveal any negative effects of anti-HSPB1 antibody on  
493 hepatocyte health in this context. Lastly, which inflammatory pathways does extracellular  
494 HSPB1 activate in the liver during CAC? We focused on TNF $\alpha$  in this study due to its strong  
495 link to AH, but HSPB1 likely also activates IL-1 $\beta$  and potentially other pro-inflammatory  
496 cytokines in CAC. Answering these questions could lead to novel diagnostic and therapeutic  
497 approaches to ALD based on targeting HSPB1. This type of strategy could identify patients at  
498 risk of severe inflammatory liver disease and short-circuit inflammation to protect the liver  
499 against life-threatening injury.

500

## 501 **MATERIALS AND METHODS**

### 502 **Human subjects**

503 Study protocols were approved by the Institutional Review Boards (IRB) at the Cleveland  
504 Clinic and MetroHealth Hospitals. All procedures were performed according to the IRB  
505 guidelines and all subjects provided written informed consent.

506

507 *Human serum samples.* Enrolled patients had confirmed diagnosis of ALD by clinicians based on  
508 medical history, physical examination, and laboratory results, according to the guidelines of the  
509 American College of Gastroenterology (<https://gi.org/clinical-guidelines/>). Healthy controls  
510 (HC) were recruited from the Clinical Research Unit at the Cleveland Clinic. Serum was  
511 collected in gold top tubes and allowed to clot for 30 minutes at room temperature. Samples were  
512 then centrifuged for 10 minutes at 4°C. Aliquots were frozen at -80°C until use. Descriptive  
513 demographic and clinical data from these patients are provided in Tables 1-3.

514

515 *Human liver samples.* Healthy control and alcohol-associated hepatitis liver samples were  
516 provided by the NIAAA R24 Clinical Resource for Alcohol-associated Hepatitis Investigations  
517 at Johns Hopkins University. The resource provided liver from 5 patients with severe AH and 5  
518 healthy donors that was obtained during liver transplantation. Tissues were snap frozen in liquid  
519 nitrogen and stored at -80°C prior to use. Descriptive demographic and clinical data from these  
520 patients are provided in Table 4.

521



522 *Human liver RNA-seq data and analysis.* RNA transcripts were obtained from the InTEAM  
523 Consortium – Alcoholic Hepatitis dbGaP Study, Accession phs001807.v1.p1. Transcripts per  
524 million (TPMs) for visualization were calculated as follows. Raw counts were normalized by  
525 dividing the counts by the length of each gene in kilobases to obtain reads per kilobases (RPK).  
526 The total RPK values in a sample were summed and then divided by 1,000,000 to give the “per  
527 million” scaling factor. Log<sub>2</sub> fold changes were calculated by running raw counts through the  
528 DESeq2 pipeline in R (v 4.2.2).

529

### 530 **Animal studies**

531 All animal protocols were approved by the Cleveland Clinic Institutional Animal Care and  
532 Use Committee. Mice used in this study were C57BL/6 mice (Strain 000664) purchased from  
533 Jackson Laboratories and maintained under specific pathogen free (SPF) conditions. Mice were  
534 allowed to acclimate to the Cleveland Clinic animal facility for 5 days prior to the start of  
535 studies. All animal experiments were performed two independent times using female mice  
536 between 6 and 12 weeks of age. Female mice were chosen because of published data  
537 demonstrating that ALD is more severe in female mice and humans. Mice were housed under a  
538 12-hour light/dark cycle in shoe-box cages (2 animals/cage) with microisolator lids and fed  
539 standard laboratory chow. Standard microisolator handling procedures were used throughout the  
540 study.

541 *Lieber-DeCarli Diet model of chronic alcohol consumption.* Mice were randomized into ethanol-  
542 fed (EtOH) and pair-fed (Pair/Control) groups and then adapted to the base liquid diet (Dyets,  
543 Bethlehem, PA; 710260) for 2 days. The EtOH group was then allowed free access to the base  
544 diet that contained increasing concentrations of EtOH over time: 1% and 2% (vol/vol) each for  
545 2 days, then 4 and 5% EtOH each for 7 days, and finally 6% EtOH for another 7 days. The 6%  
546 (vol/vol) diet provided EtOH as 32% of total calories in the diet. Control mice were pair-fed diets  
547 which isocalorically substituted maltodextrin for EtOH over the entire feeding period. At the end  
548 of the study, mice were anesthetized, blood samples were obtained from the posterior vena cava  
549 using nonheparinized syringes, livers were excised, and the mice were euthanized by  
550 exsanguination.

551 *Mouse liver protein isolation.* Snap frozen liver sections were placed into microcentrifuge tubes  
552 with 400  $\mu$ L of tissue lysis buffer (Cell Signaling, 9803S) supplemented with protease inhibitor  
553 (Roche, 11836170001) and placed on ice. Livers were homogenized using a Tissue-Tearor.  
554 Protein concentration was determined by BCA (Pierce, 23228).

555

#### 556 **Cell culture studies**

557 All cell lines were obtained directly from American Type Culture Collection (ATCC) or  
558 from the Cleveland Clinic Cell Culture Core which obtained them directly from ATCC. Cell  
559 phenotypes were routinely monitored, and cells were periodically tested for mycoplasma  
560 contamination.

561 *HSPB1 recombinant protein.* HEK293 cells were transfected with an endotoxin-free prep  
562 (Takara Bio, 740426.50) of HSPB1-FLAG DNA (Genecopoeia, EX-I0586-M39) using TransIT-  
563 293 (Mirus Bio, MIR2705) according to the manufacturer's protocol. Cells were transfected for  
564 72 hours, then lysate was collected in TBS + 1 mM DTT supplemented with 1x Protease  
565 Inhibitor Cocktail (Roche, 11836170001). Lysates were sonicated on ice (1 min total time on; 10  
566 seconds on/10 seconds off; Amp= 30%) and centrifuged at 15,000 x G for 20 min at 4 °C. The  
567 supernatant was then dialyzed overnight into TBS + 0.15 M NaCl, pH 7. The dialyzed  
568 supernatant was then directly applied onto 1mL bed of pre-equilibrated ANTI-FLAG® M2  
569 Affinity Gel resin (Sigma, A2220). After allowing the protein to bind by gravity flow, the  
570 column was washed with 15 column volumes of TBS. HSPB1-FLAG was eluted by pouring five  
571 1 bed volumes worth of 0.1M Glycine-HCl, pH 3.5. Five elution fractions were collected in 5  
572 sequential 1.5 mL microcentrifuge tubes, each containing 50  $\mu$ l of 0.1M Tris pH 8.0 to neutralize  
573 acid. Elution fractions were pooled together and spun down in 10 kDa spin concentrator to  
574 increase concentration, then buffer exchanged into HEPES storage buffer. Protein was then  
575 stored at 4°C.

576 *Ethanol stress in hepatocytes.* HepG2 hepatocytes were seeded into a 6-well tissue culture plate  
577 at 250,000 cells per well. The following day, the media was removed from the wells and the cells  
578 were treated with either 500  $\mu$ L of 2.5 mM (1.5%) ethanol in serum-free EMEM or 500  $\mu$ L  
579 serum-free EMEM for 1 hour at 37°C and 5% CO<sub>2</sub>. After ethanol stress, the supernatant was  
580 removed from the cells and frozen at -80°C until use. The cells were then scraped off the plate

581 with a disposable cell scraper into 300  $\mu$ L of PBS, pipetted up and down to homogenize lysate,  
582 and then frozen at  $-80^{\circ}\text{C}$  until use.

583  
584 *Hepatocytes stressed with ethanol in the presence of 4-methylpyrazole (4-MP).* HepG2 or  
585 AML12 hepatocytes were seeded into a 6-well tissue culture plate at 250,000 cells per well. The  
586 following day, the media was removed from the wells, and the cells were treated with 500  $\mu$ L of  
587 2.5 mM (1.5%) ethanol in serum-free EMEM, 5 mM 4MP in 500  $\mu$ L of serum-free EMEM, or  
588 500  $\mu$ L serum-free EMEM for 1 hour at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$ . After incubation, the supernatant was  
589 removed from the cells and frozen at  $-80^{\circ}\text{C}$  until use. The cells were then scraped off the plate  
590 with a disposable cell scraper into 300  $\mu$ L of PBS, pipetted up and down to homogenize lysate,  
591 and then frozen at  $-80^{\circ}\text{C}$  until use.

592  
593 *Ethanol stress in macrophages treated with recombinant human HSPB1.* RAW264.7  
594 macrophages were seeded into a 6-well tissue culture plate at 250,000 cells per well. The  
595 following day, the media was removed from the wells and the cells were treated with 500  $\mu$ L of  
596 2.5 mM (1.5%) ethanol in serum-free DMEM, 3  $\mu$ M HSPB1 in 500  $\mu$ L of serum-free DMEM, 3  
597  $\mu$ M HSPB1, and 2.5 mM ethanol in serum-free DMEM, or 500  $\mu$ L of DMEM for 1 hour or 24  
598 hours at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$ .

599  
600 *Macrophages exposed to media conditioned by ethanol stressed hepatocytes and treated with*  
601 *anti-HSPB1 antibody.* Two T75 tissue culture flasks containing HepG2 hepatocytes ( $\sim 70$ - $80\%$   
602 confluent) were treated with 10 mL of serum-free DMEM or 10 mL of serum-free DMEM  
603 containing 2.5 mM (1.5%) ethanol for 24 hours at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$ . The conditioned media was  
604 then removed from the culture flasks and split in half. Half of the media was used as a control  
605 and the other half was incubated with 2.5 mg/mL anti-HSPB1 antibody (Custom antibody  
606 produced by Biomatik). Both control and antibody treated media samples were rotated overnight  
607 at  $4^{\circ}\text{C}$ . RAW264.7 macrophages were plated the day prior to conditioned media collection at  
608 250,000 cells per well in a 6 well tissue culture dish in DMEM supplemented with 10% FBS.  
609 After preparation of the treated and control conditioned media, the complete media was removed  
610 from the RAW264.7 cells. The RAW264.7 cells were then treated with 500  $\mu$ L of serum-free  
611 DMEM (negative experimental control), serum-free DMEM with 2.5mM ethanol (positive

612 experimental control), non-ethanol treated HepG2 conditioned media, non-ethanol treated  
613 HepG2 conditioned media with anti-HSPB1 antibody, ethanol treated HepG2 conditioned media,  
614 or ethanol treated HepG2 conditioned media with anti-HSPB1 antibody for 1 hour at 37°C and  
615 5% CO<sub>2</sub>.

616

### 617 **HSPB1 assays**

618 *HSPB1 and phosphorylated-HSPB1 in human serum by ELISA.* For measurement of HSPB1,  
619 serum samples were diluted 1:4 in reagent diluent and the ELISA completed per the  
620 manufacture's protocol (R&D, DY1580). For measurement of phosphorylated-HSPB1  
621 (S78/S82), serum samples were diluted 1:2 in reagent diluent and the ELISA completed per the  
622 manufacture's protocol (R&D, DYC2314-2).

623

624 *HSPB1 in murine liver by ELISA.* 100 µL of lysate (normalized by protein concentration) was  
625 loaded in triplicate onto a high-binding polystyrene plate (Costar, 07-200-39) and incubated  
626 overnight at 4°C. The following day, lysate was decanted, and the plate washed once with 200  
627 µL per well of PBS with 0.01% Tween-20. The plate was blocked using 1% BSA in PBS (200  
628 µL per well) for 1.5 hours at room temperature. After blocking, 50 µL of 0.63 mg/mL anti-  
629 HSPB1 antibody (Biomatik) was added to the plate and incubated for 2 hours at room  
630 temperature. After primary antibody incubation, the plate was washed 3 times with 200 µL of  
631 PBS with 0.01% Tween-20 per well. Then 50 µL of secondary antibody conjugated with  
632 horseradish peroxidase (Jackson ImmunoResearch, 711-035-152) was added to the plate at a final  
633 concentration of 0.08 mg/mL for 1 hour. The plate was then again washed 3 times with PBS with  
634 0.01% Tween-20 and 50 µL of pre-warmed TMB was added to the plate. The detection reagent  
635 was developed for 5 minutes at room temperature and then the reaction was quenched with 50  
636 µL of 0.5M sulfuric acid. The plate was then read at 450<sub>nm</sub> on a spectrophotometer (Synergy).

637

638 *qRT-PCR for HSPB1 in murine liver.* Total RNA was isolated from snap frozen liver samples by  
639 Trizol:chloroform extraction as per the manufacturer's protocol (Invitrogen, 15596026), then  
640 precipitated using glycoblue, 3M sodium acetate and isopropanol. After washing twice with 80%  
641 ethanol, the RNA pellet was resuspended in nuclease free water and further purified using an  
642 RNA Clean and Concentrate column as per manufacturer protocol (Zymo Research, R1013). 1

643 mg of total RNA per sample was reverse transcribed (SuperScript IV Reverse Transcriptase,  
644 oligo dT primers, ThermoFisher, 18091050), and quantitative PCR performed on a QuantStudio  
645 6 Flex Real-Time PCR System (Applied Biosystems) using TaqMan Fast Advanced Master Mix  
646 (Applied Biosystems, 4444557) and TaqMan probes for *Hspb1* (ThermoFisher,  
647 MM00834384\_G1) and *Gapdh* (ThermoFisher, MM99999915\_G1). *Hspb1* transcript levels were  
648 normalized to *Gapdh* and fold changes were calculated using the delta-delta CT method.

649  
650 *qRT-PCR for HSPB1 in HepG2 cells.* At the end of experiments described above, media was  
651 removed from the cells, and cells were gently rinsed once with 500  $\mu$ L of DPBS (Dubbucco's  
652 phosphate buffered saline, Genesee, 25-508). DPBS was removed and 200  $\mu$ L of RNAlater  
653 (Invitrogen, AM7020) was added to each well. Cells were scraped off and collected into a  
654 microcentrifuge tube. RNA was isolated using PureLink RNA mini kit (Ambion, 12-183-018A)  
655 per the manufacturer's instructions. 1 mg of total RNA per sample was reverse transcribed  
656 (Applied Biosystems, 43-688-14) and quantitative PCR performed on a CFX96 Touch Real-  
657 Time PCR system (Bio-Rad). Primer sequences: *Hspb1* Forward -  
658 5'AAGCTAGCCACGCAGTCCAA3'; *Hspb1* Reverse -5'CGACTCGAAGGTGACTGGGA3';  
659 *Gapdh* Forward -5'TGGTATCGTGGAAGGACTCATGAC3'; *Gapdh* Reverse -  
660 5'ATGCCAGTGAGCTTCCCGTTCAGC3'. Transcript levels were normalized to *Gapdh* and  
661 fold changes were calculated using the delta-delta CT method.

662  
663 *Immunostaining for HSPB1 in murine liver.* Formalin-fixed paraffin embedded liver was sliced  
664 into 5  $\mu$ m sections and placed on glass slides. The slides were heated to 60°C on a heat block for  
665 30 minutes and then submerged 3 times for 5 minutes in xylene. The slides were then rehydrated  
666 by submerging them 30 times in 95% ethanol followed by 15 submersions in 70% ethanol, and  
667 finally, submersion for 1 minute in deionized water. Slides were washed 2 times in TBS with  
668 0.01% Tween-20 for 5 minutes and then underwent antigen retrieval by steaming submerged in  
669 sodium citrate for 20 minutes followed by a 1-hour cooling period. After steaming, a  
670 hydrophobic border was drawn around the tissue with a PAP pen and slides were blocked with  
671 Superior blocking buffer (G-Biosciences, 786-660) for 1 hour at room temperature. Anti-HSPB1  
672 antibody (Biomatik) was added to the slides at a final concentration of 1.26 mg/mL and left to  
673 incubate overnight at 4°C in a humid chamber. The following day, slides were washed for 15

674 minutes total in TBS with 0.01% Tween-20. Anti-rabbit Alexa Fluor 647 conjugated secondary  
675 antibody was added to the slides at a final concentration of 0.9 mg/mL and incubated for 30  
676 minutes at room temperature protected from light (protection from light continued from this  
677 point forward). Slides were washed again for 15 minutes total in TBS with 0.01% Tween-20 and  
678 then counterstained with 10 mg/mL bisBenzimide H (Sigma-Aldrich, 33258) dissolved in TBS  
679 for 20 minutes at room temperature. Finally, slides were washed for 5 minutes with deionized  
680 water and cover slipped. All immunofluorescent sections were imaged using either a widefield  
681 fluorescent microscope (Keyence BZ-800) or an inverted confocal microscope (40x/1.25 oil  
682 objective on a Leica TCS-SP8-AOBS inverted confocal microscope (Leica Microsystems,  
683 GmbH, Wetzlar, Germany)).

684  
685 *HSPB1 in hepatocytes by ELISA.* Cell culture media or cell lysates were thawed on ice and then  
686 normalized to protein content by BCA assay (Pierce, 23228). HSPB1 concentration was  
687 measured in human cells (HepG2) with the R&D Human HSP27 DuoSet ELISA kit (DY1580)  
688 according to the manufacturer's protocol. HSPB1 concentration was measured in murine cells  
689 (AML12) using the same protocol described for the murine liver samples.

690  
691 *Immunoblotting for HSPB1.* Cell or liver lysates were boiled in Laemmli buffer containing 10%  
692 b-mercaptoethanol for 10 minutes. SDS-PAGE Gel electrophoresis was performed using 12%  
693 NuPage Bis-Tris gels with MOPS buffers. Proteins were transferred to PVDF membranes and  
694 blocked with LiCOR Intercept PBS blocking buffer (LiCor, 927-70003) for 1 hour. Membranes  
695 were then incubated in blocking buffer containing 0.63 mg/mL anti-HSPB1 antibody (Biomatik)  
696 and 0.282 mg/mL anti-GAPDH antibody (Cell Signaling, D4C6R) overnight at 4°C with  
697 agitation. The membranes were washed 3 times with PBS with 0.01% Tween-20 for 5 minutes  
698 each wash and then incubated with 0.2 mg/mL 680RD (LI-COR, 926-68023) anti-rabbit or 0.2  
699 mg/mL 800RD (LI-COR, 926-32212) anti-mouse secondary antibody in blocking buffer for one  
700 hour. Membranes were then again washed 3 times with PBS with 0.01% Tween-20 for 5 minutes  
701 and fluorescent signal was detected using an LI-COR Odyssey CLX machine and LI-COR  
702 Acquisition software. Densitometry was performed using ImageJ.

703

704 **Other assays**

705 *Liver Triglycerides*. Measured pieces of liver (80-85mg) were digested in 3 M KOH at 70°C for  
706 1 hour then left overnight at room temperature. The next day the total volume was brought to  
707 500  $\mu$ L with 2M Tris-HCl pH 7.5 and then diluted 1:5 with 2M Tris-HCl pH 7.5. 10  $\mu$ L of  
708 diluted sample was added to of 1 mL of pre-warmed GPO triglyceride reagent (Pointe Scientific  
709 Inc., T7532-500). After a 5-minute incubation, samples were read on a spectrophotometer at 500  
710 nm.

711  
712 *Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)*. For both assays, murine  
713 serum was thawed on ice. For AST, 5  $\mu$ L serum was added to 100  $\mu$ L of AST reagent (Sekisui  
714 Diagnostics, 319-30) and read on a spectrophotometer at 340nm every 30 seconds for 20  
715 minutes. For ALT, 10  $\mu$ L serum was added to 90  $\mu$ L of ALT reagent (Sekisui Diagnostics, 318-  
716 30) and read on a spectrophotometer at 340nm every 30 seconds for 30 minutes.

717  
718 *TNF $\alpha$  ELISA in cell culture supernatants*. At the end of experiments described above, cell media  
719 was collected and TNF $\alpha$  concentrations measured using the Mouse TNF-alpha Quantikine  
720 ELISA Kit (R&D, #MTA00B) according to manufacturer's protocol and recommendations.

## 721 722 **Statistics**

723 Values shown in all figures represent the means  $\pm$  SD, except figures 2C, D, and E which  
724 represent the means  $\pm$  SEM. Pairwise differences were evaluated using parametric or non-  
725 parametric two-tailed t-tests as appropriate. Differences among multiple groups was detected  
726 using one-way ANOVAs with post-hoc analysis. Statistical analysis was performed using  
727 GraphPad Prism (v.10.2.2), except analysis in figures 2C-E, which was performed using R (v  
728 4.2.2). A *P* value of less than 0.05 was considered significant.

729  
730  
731  
732

733 **REFERENCES**

- 734 1. Alcohol-induced Death Rates in the United States, 2019–2020. Hyattsville, MD:  
735 <https://dx.doi.org/10.15620/cdc:121795>, 2022.
- 736 2. Niu X, Zhu L, Xu Y, et al. Global prevalence, incidence, and outcomes of alcohol related  
737 liver diseases: a systematic review and meta-analysis. *BMC Public Health* 2023;23:859.
- 738 3. Centers for Disease Control and Prevention. Alcohol Related Disease Impact (ARDI)  
739 application, 2024. [www.cdc.gov/ARDI](http://www.cdc.gov/ARDI), 2024.
- 740 4. Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection  
741 as the Leading Indication for Liver Transplantation in the United States. *Clin*  
742 *Gastroenterol Hepatol* 2018;16:1356-1358.
- 743 5. Dang K, Hirode G, Singal AK, et al. Alcoholic Liver Disease Epidemiology in the United  
744 States: A Retrospective Analysis of 3 US Databases. *Am J Gastroenterol* 2020;115:96-  
745 104.
- 746 6. Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated  
747 Liver Disease. *Official journal of the American College of Gastroenterology | ACG*  
748 2024;119:30-54.
- 749 7. Rachakonda V, Bataller R, Duarte-Rojo A. Recent advances in alcoholic hepatitis.  
750 *F1000Res* 2020;9.
- 751 8. Yamazaki T, Schnabl B. Acute alcohol-associated hepatitis: Latest findings in non-  
752 invasive biomarkers and treatment. *Liver International* 2023;n/a.
- 753 9. Mackowiak B, Fu Y, Maccioni L, et al. Alcohol-associated liver disease. *J Clin Invest*  
754 2024;134.
- 755 10. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from  
756 pathogenesis to novel therapeutic strategies. *Cell Mol Immunol* 2016;13:316-27.
- 757 11. Wen Y, Lambrecht J, Ju C, et al. Hepatic macrophages in liver homeostasis and diseases-  
758 diversity, plasticity and therapeutic opportunities. *Cellular & Molecular Immunology*  
759 2021;18:45-56.
- 760 12. Ju C, Mandrekar P. Macrophages and Alcohol-Related Liver Inflammation. *Alcohol Res*  
761 2015;37:251-62.
- 762 13. Wang HJ, Gao B, Zakhari S, et al. Inflammation in alcoholic liver disease. *Annu Rev*  
763 *Nutr* 2012;32:343-68.



- 764 14. Kubes P, Mehal WZ. Sterile Inflammation in the Liver. *Gastroenterology*  
765 2012;143:1158-1172.
- 766 15. Han H, Desert R, Das S, et al. Danger signals in liver injury and restoration of  
767 homeostasis. *J Hepatol* 2020;73:933-951.
- 768 16. Kojima K, Musch MW, Ropeleski MJ, et al. Escherichia coli LPS induces heat shock  
769 protein 25 in intestinal epithelial cells through MAP kinase activation. *Am J Physiol*  
770 *Gastrointest Liver Physiol* 2004;286:G645-52.
- 771 17. Petrof EO, Musch MW, Ciancio M, et al. Flagellin is required for salmonella-induced  
772 expression of heat shock protein Hsp25 in intestinal epithelium. *Am J Physiol*  
773 *Gastrointest Liver Physiol* 2008;294:G808-18.
- 774 18. Wang N, Liu X, Liu K, et al. Homo-oxidized HSPB1 protects H9c2 cells against  
775 oxidative stress via activation of KEAP1/NRF2 signaling pathway. *iScience*  
776 2023;26:107443.
- 777 19. Arrigo AP. Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology  
778 and environment of the cell. *Cell Stress Chaperones* 2017;22:517-529.
- 779 20. Acunzo J, Katsogiannou M, Rocchi P. Small heat shock proteins HSP27 (HspB1),  $\alpha$ B-  
780 crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. *Int J Biochem Cell*  
781 *Biol* 2012;44:1622-31.
- 782 21. Tan HK, Yates E, Lilly K, et al. Oxidative stress in alcohol-related liver disease. *World J*  
783 *Hepatol* 2020;12:332-349.
- 784 22. Paul C, Simon S, Gibert B, et al. Dynamic processes that reflect anti-apoptotic strategies  
785 set up by HspB1 (Hsp27). *Exp Cell Res* 2010;316:1535-52.
- 786 23. Pignataro L, Varodayan FP, Tannenholz LE, et al. Brief alcohol exposure alters  
787 transcription in astrocytes via the heat shock pathway. *Brain Behav* 2013;3:114-33.
- 788 24. Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: a potential biomarker for  
789 hepatocellular carcinoma identified by serum proteome analysis. *Proteomics*  
790 2005;5:4581-8.
- 791 25. Gruden G, Carucci P, Barutta F, et al. Serum levels of anti-heat shock protein 27  
792 antibodies in patients with chronic liver disease. *Cell Stress Chaperones* 2021;26:151-  
793 157.

- 794 26. Gruden G, Carucci P, Lolli V, et al. Serum heat shock protein 27 levels in patients with  
795 hepatocellular carcinoma. *Cell Stress Chaperones* 2013;18:235-41.
- 796 27. Liang C, Xu Y, Ge H, et al. The clinicopathological and prognostic value of HSP27 in  
797 hepatocellular carcinoma: a systematic review and meta-analysis. *Onco Targets Ther*  
798 2018;11:1293-1303.
- 799 28. Long S, Peng F, Song B, et al. Heat Shock Protein Beta 1 is a Prognostic Biomarker and  
800 Correlated with Immune Infiltrates in Hepatocellular Carcinoma. *Int J Gen Med*  
801 2021;14:5483-5492.
- 802 29. De Maio A, Cauvi DM, Capone R, et al. The small heat shock proteins, HSPB1 and  
803 HSPB5, interact differently with lipid membranes. *Cell Stress Chaperones* 2019;24:947-  
804 956.
- 805 30. Yang F, Beltran-Lobo P, Sung K, et al. Reactive astrocytes secrete the chaperone HSPB1  
806 to mediate neuroprotection. *Sci Adv* 2024;10:eadk9884.
- 807 31. Batulan Z, Pulakazhi Venu VK, Li Y, et al. Extracellular Release and Signaling by Heat  
808 Shock Protein 27: Role in Modifying Vascular Inflammation. *Front Immunol* 2016;7:285.
- 809 32. Salari S, Seibert T, Chen YX, et al. Extracellular HSP27 acts as a signaling molecule to  
810 activate NF- $\kappa$ B in macrophages. *Cell Stress Chaperones* 2013;18:53-63.
- 811 33. Ogbodo E, Michelangeli F, Williams JHH. Exogenous heat shock proteins HSPA1A and  
812 HSPB1 regulate TNF- $\alpha$ , IL-1 $\beta$  and IL-10 secretion from monocytic cells. *FEBS Open*  
813 *Bio* 2023;13:1922-1940.
- 814 34. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases,  
815 functions and pathology. *Cell Mol Life Sci* 2009;66:3289-307.
- 816 35. Hyun J, Han J, Lee C, et al. Pathophysiological Aspects of Alcohol Metabolism in the  
817 Liver. *Int J Mol Sci* 2021;22.
- 818 36. Zou Y, Shi H, Liu N, et al. Mechanistic insights into heat shock protein 27, a potential  
819 therapeutic target for cardiovascular diseases. *Front Cardiovasc Med* 2023;10:1195464.
- 820 37. Sookoian S, Castaño GO, Scian R, et al. Heat Shock Protein 27 is down-regulated in  
821 Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). *Sci Rep*  
822 2016;6:22528.

- 823 38. Bălănescu A, Bălănescu PC, Codreanu IF, et al. Exploring the Role of Serum Osteonectin  
824 and Hsp27 in Pediatric MAFLD Diagnosis and Cardiometabolic Health. *Nutrients*  
825 2024;16.
- 826 39. Guo F, Zheng K, Benedé-Ubieto R, et al. The Lieber-DeCarli Diet-A Flagship Model for  
827 Experimental Alcoholic Liver Disease. *Alcohol Clin Exp Res* 2018;42:1828-1840.
- 828 40. Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. *J*  
829 *Hepatol* 2019;70:249-259.
- 830 41. Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty  
831 liver. *World J Gastroenterol* 2014;20:14672-85.
- 832 42. Cunningham RP, Porat-Shliom N. Liver Zonation - Revisiting Old Questions With New  
833 Technologies. *Front Physiol* 2021;12:732929.
- 834 43. Kammoun M, Picard B, Astruc T, et al. The Invalidation of HspB1 Gene in Mouse Alters  
835 the Ultrastructural Phenotype of Muscles. *PLoS One* 2016;11:e0158644.
- 836 44. Alagar Boopathy LR, Jacob-Tomas S, Alecki C, et al. Mechanisms tailoring the  
837 expression of heat shock proteins to proteostasis challenges. *J Biol Chem*  
838 2022;298:101796.
- 839 45. Rini DM, Yamamoto Y, Suzuki T. Partially hydrolyzed guar gum upregulates heat shock  
840 protein 27 in intestinal Caco-2 cells and mouse intestine via mTOR and ERK signaling. *J*  
841 *Sci Food Agric* 2023;103:5165-5170.
- 842 46. Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation. *Semin*  
843 *Immunopathol* 2022;44:445-459.
- 844 47. Federico A, Tuccillo C, Terracciano F, et al. Heat shock protein 27 expression in patients  
845 with chronic liver damage. *Immunobiology* 2005;209:729-35.
- 846 48. Nagy LE. Stabilization of tumor necrosis factor-alpha mRNA in macrophages in response  
847 to chronic ethanol exposure. *Alcohol* 2004;33:229-33.
- 848 49. Jin C, Cleveland JC, Ao L, et al. Human myocardium releases heat shock protein 27  
849 (HSP27) after global ischemia: the proinflammatory effect of extracellular HSP27  
850 through toll-like receptor (TLR)-2 and TLR4. *Mol Med* 2014;20:280-9.
- 851 50. Giuliano JS, Jr., Lahni PM, Wong HR, et al. Pediatric Sepsis - Part V: Extracellular Heat  
852 Shock Proteins: Alarmins for the Host Immune System. *Open Inflamm J* 2011;4:49-60.

- 853 51. Feng D, Hwang S, Guillot A, et al. Inflammation in Alcohol-Associated Hepatitis:  
854 Pathogenesis and Therapeutic Targets. *Cell Mol Gastroenterol Hepatol* 2024;18:101352.
- 855 52. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe  
856 alcoholic hepatitis. *Ann Intern Med* 1990;112:917-20.
- 857 53. Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1  
858 and interleukin-6 concentrations in chronic alcoholic patients. *Hepatology* 1991;13:267-  
859 76.
- 860 54. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor  $\alpha$  in alcohol-  
861 induced liver injury in mice. *Gastroenterology* 1999;117:942-952.
- 862 55. Kishore R, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA  
863 by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase  
864 signaling pathway. *J Biol Chem* 2001;276:41930-7.
- 865 56. McMullen MR, Cocuzzi E, Hatzoglou M, et al. Chronic ethanol exposure increases the  
866 binding of HuR to the TNFalpha 3'-untranslated region in macrophages. *J Biol Chem*  
867 2003;278:38333-41.
- 868 57. Sun J, Zhao P, Shi Y, et al. Recent insight into the role of macrophage in alcohol-  
869 associated liver disease: a mini-review. *Front Cell Dev Biol* 2023;11:1292016.
- 870 58. Bishehsari F, Magno E, Swanson G, et al. Alcohol and Gut-Derived Inflammation.  
871 *Alcohol Res* 2017;38:163-171.
- 872 59. van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. *Nat Rev Immunol*  
873 2023;23:289-303.
- 874 60. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa  
875 attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the  
876 rat. *Hepatology* 1997;26:1530-7.
- 877 61. Blendis L, Dotan I. Anti-TNF therapy for severe acute alcoholic hepatitis: What went  
878 wrong? *Gastroenterology* 2004;127:1637-1639.
- 879 62. Boetticher NC, Peine CJ, Kwo P, et al. A Randomized, Double-Blinded, Placebo-  
880 Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis.  
881 *Gastroenterology* 2008;135:1953-1960.
- 882